Seeking Alpha

Jefferies initiates Arrowhead Research at Buy on RNAi platform potential

  • Recent private offering placement agent Jefferies initiates coverage on Arrowhead Research (ARWR +4.3%) with a Buy and PT of $15.
  • Analyst Thomas Wei believes Arrowhead's differentiated RNAi platform is its "key value driver." And, as ARC-520 for hepatitis B progresses, "it should provide confidence around safety and mechanistic validation for the technology, even if HBV cures are not achieved. We expect expansion into liver targeted orphan diseases should create significant value."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: